{"id":"tacrolimus-arm-a","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"20-40","effect":"Hypertension"},{"rate":"15-30","effect":"Hyperglycemia"},{"rate":"5-15","effect":"Tremor"},{"rate":"10-20","effect":"Headache"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"1-5","effect":"Neurotoxicity (encephalopathy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT nuclear translocation, tacrolimus suppresses the transcription of interleukin-2 and other T-cell activation genes, resulting in potent immunosuppression. This mechanism makes it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing transcription of IL-2 and other cytokine genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:52.869Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune uveitis"},{"name":"Autoimmune hepatitis"}]},"trialDetails":[{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT06692426","phase":"PHASE1","title":"Trial of Cell Based Therapy for DMD","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2025-03-20","conditions":"Duchenne Muscular Dystrophy","enrollment":8},{"nctId":"NCT00619528","phase":"NA","title":"HLA-Identical Sibling Renal Transplant Tolerance","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-01","conditions":"Immunosuppression, Kidney Transplantation, Graft Rejection","enrollment":88},{"nctId":"NCT06529536","phase":"PHASE4","title":"Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-08-05","conditions":"Solid Organ Transplant","enrollment":45},{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT06291103","phase":"PHASE2, PHASE3","title":"Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03-01","conditions":"Kidney Transplant Rejection","enrollment":290},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT06517641","phase":"PHASE2","title":"Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-05-12","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT04877288","phase":"PHASE3","title":"A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-21","conditions":"Renal Allograft Recipients","enrollment":102},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT03979365","phase":"PHASE4","title":"Envarsus XR Compared to Immediate Release Tacrolimus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-18","conditions":"Kidney Transplant Recipients","enrollment":261},{"nctId":"NCT01349101","phase":"PHASE2","title":"A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-02-10","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT01743131","phase":"PHASE2","title":"Abatacept as GVHD Prophylaxis Phase 2","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-02-01","conditions":"Graft vs Host Disease, Malignancy","enrollment":186},{"nctId":"NCT05907746","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-29","conditions":"GATA2, Immunodeficiency","enrollment":7},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma","enrollment":63},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":"Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":68},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT06701825","phase":"PHASE4","title":"Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2025-06-02","conditions":"Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression","enrollment":114},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT01889381","phase":"PHASE2","title":"Human Craniomaxillofacial Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries","enrollment":15},{"nctId":"NCT07053462","phase":"PHASE1, PHASE2","title":"CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk","status":"RECRUITING","sponsor":"AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC","startDate":"2025-06-01","conditions":"End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant","enrollment":90},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06900777","phase":"NA","title":"Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-04-01","conditions":"Vitiligo, Child, Progressive Disease","enrollment":90},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT01459107","phase":"PHASE2","title":"Human Upper Extremity Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2011-07-21","conditions":"Amputation, Traumatic, Wounds and Injuries, Hand Injuries","enrollment":30},{"nctId":"NCT06960824","phase":"","title":"Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Chiesi SAS","startDate":"2025-05","conditions":"Chronic Renal Disease","enrollment":165},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT04720326","phase":"PHASE4","title":"Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Edward Geissler","startDate":"2020-12-23","conditions":"Prophylaxis Against Liver Transplant Rejection","enrollment":268},{"nctId":"NCT04561986","phase":"PHASE3","title":"TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Antibody-mediated Rejection","enrollment":50},{"nctId":"NCT00866684","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-01-01","conditions":"Skin Cancer","enrollment":44},{"nctId":"NCT04314219","phase":"PHASE3","title":"Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients","status":"RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2021-08-15","conditions":"Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission","enrollment":264},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT06777719","phase":"PHASE1","title":"Eight-Treg Study:Trial of Adoptive Immunotherapy With Autologous ex Vivo Expanded Regulatory CD8+ T Cells in Living Donor Kidney Transplant Recipients","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-02-01","conditions":"Kidney Transplantation","enrollment":9},{"nctId":"NCT04380311","phase":"NA","title":"Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2020-05-01","conditions":"Heart Transplant Failure and Rejection","enrollment":15},{"nctId":"NCT05655273","phase":"PHASE4","title":"Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"University Health Network, Toronto","startDate":"2024-01-01","conditions":"Liver Transplant Rejection, Immune System Suppression","enrollment":40},{"nctId":"NCT06019507","phase":"PHASE2","title":"A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2022-06-29","conditions":"Liver Transplantation","enrollment":12},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT04825262","phase":"NA","title":"Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2021-02-01","conditions":"Kidney Transplant Rejection, Kidney Transplant; Complications","enrollment":74},{"nctId":"NCT06676696","phase":"PHASE4","title":"Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-22","conditions":"Renal Failure , Chronic, Graft Failure, Graft Rejection","enrollment":202},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT01304836","phase":"PHASE4","title":"A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-22","conditions":"Kidney Transplantation","enrollment":1166},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT04711291","phase":"NA","title":"Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Medication Adherence, Renal Transplant","enrollment":""},{"nctId":"NCT03605654","phase":"PHASE2, PHASE3","title":"Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants","status":"WITHDRAWN","sponsor":"Medeor Therapeutics, Inc.","startDate":"2024-12","conditions":"Kidney Transplant Rejection","enrollment":""},{"nctId":"NCT06438679","phase":"PHASE4","title":"3T Therapy in the Treatment of MDA5-positive Dermatomyositis","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-03-19","conditions":"Dermatomyositis","enrollment":133},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT04207177","phase":"PHASE4","title":"Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2019-10-30","conditions":"Kidney Transplant; Complications, Immune Suppression","enrollment":100},{"nctId":"NCT02498977","phase":"PHASE4","title":"Liver Immunosuppression Free Trial","status":"TERMINATED","sponsor":"King's College London","startDate":"2015-10","conditions":"Transplantation, Liver","enrollment":116},{"nctId":"NCT05396898","phase":"PHASE4","title":"Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2020-12-16","conditions":"Posttransplant Diabetes Mellitus","enrollment":44},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT04936282","phase":"PHASE4","title":"Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)","status":"UNKNOWN","sponsor":"Fundación Canaria de Investigación Sanitaria","startDate":"2022-07-05","conditions":"Kidney Transplant Failure and Rejection","enrollment":80},{"nctId":"NCT06147648","phase":"PHASE4","title":"Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-12-01","conditions":"Liver Transplantation","enrollment":352},{"nctId":"NCT04048161","phase":"PHASE4","title":"Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome","status":"COMPLETED","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2019-11-12","conditions":"Nephrotic Syndrome in Children","enrollment":270},{"nctId":"NCT05913596","phase":"NA","title":"The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-05-23","conditions":"Antibody-mediated Rejection, Kidney Tranplant","enrollment":15},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT04063865","phase":"PHASE3","title":"Everolimus Monotherapy as Immunosuppression After Liver Transplant","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-05-09","conditions":"Kidney Failure","enrollment":14},{"nctId":"NCT05073822","phase":"PHASE1, PHASE2","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2023-02-20","conditions":"Renal Transplant Rejection, Renal Transplant Infection","enrollment":""},{"nctId":"NCT04415476","phase":"PHASE2","title":"Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-06-30","conditions":"Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity","enrollment":""},{"nctId":"NCT02866682","phase":"PHASE4","title":"Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2018-03-01","conditions":"Renal Transplant Rejection","enrollment":176},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT05423496","phase":"NA","title":"KidneyCare Immuno-optimization in Renal Allografts (KIRA)","status":"WITHDRAWN","sponsor":"CareDx","startDate":"2022-08","conditions":"Kidney Transplant, Immunosuppression, Allograft","enrollment":""},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT03266393","phase":"PHASE4","title":"Envarsus XR® in Adolescent Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2019-01-15","conditions":"Kidney Transplantation, Renal Transplantation, Grafting, Kidney","enrollment":28},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT00995059","phase":"PHASE1, PHASE2","title":"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"","conditions":"Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf"],"phase":"marketed","status":"active","brandName":"Tacrolimus (Arm A)","genericName":"Tacrolimus (Arm A)","companyName":"Weill Medical College of Cornell University","companyId":"weill-medical-college-of-cornell-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a small molecule inhibitor of the FK506-binding protein 1A, which is involved in the regulation of the immune system. It is used to treat conditions such as Graft vs Host Disease, Malignancy, Immunosuppression, Kidney Transplantation, and Liver Transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}